Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Lansdale: HAYES, Inc.. Health Technology Brief Publication. 2013 Authors' conclusions Crohn's disease (CD) and ulcerative colitis (UC) are progressive, inflammatory disorders of the gastrointestinal tract characterized by strictures, fistulae, abdominal pain, abnormal bowel function, and rectal bleeding. CD is usually diagnosed in young adulthood, and the incidence and prevalence of the disease have increased slightly in recent decades. In the adult population of the United States, the prevalence of CD is 241 per 100,000 individuals and the prevalence of UC is 263 per 100,000 individuals. UC tends to be more severe in younger patients, particularly children. Both disorders are associated with development of colorectal cancer. The major goal of treatment for IBD is mucosal healing using medical therapy. In the 9% to 35% of patients with UC in whom medical therapy fails, the treatment is colectomy. Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents, Non-Steroidals; Antibodies, Monoclonal; Inflammatory Bowel Diseases Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32013000587 Date abstract record published 29/07/2013 |